Krishnamurthy S, Dayal Y
Department of Pathology, New England Medical Center, Boston, Massachusetts 02111, U.S.A.
Am J Surg Pathol. 1997 Mar;21(3):327-33. doi: 10.1097/00000478-199703000-00009.
Transforming growth factor-alpha (TGF-alpha), a potent growth factor belonging to the epidermal growth factor family, exerts its role in the proliferation and differentiation of normal and neoplastic cells by binding to epidermal growth factor receptor (EGFR). Coexpression of TGF-alpha and EGFR in carcinomas is believed to confer growth advantage to tumor cells. To evaluate their role in such indolent tumors as gastrointestinal (GI) carcinoids, we investigated the immunohistochemical expression of TGF-alpha and EGFR in 25 GI carcinoids (nine foregut, 13 midgut, and three hindgut) and studied the correlation of their expression with the secretory and clinicopathologic profiles of these tumors. TGF-alpha was expressed in 18 (72%) of these tumors, and whereas 16 of 17 tumors showed immunopositivity for the extracellular domain of EGFR, none expressed its intracellular domain. Ten TGF-alpha-positive tumors were positive for serotonin, seven for somatostatin, three for calcitonin, and one tumor each for gastrin, glucagon, pancreatic polypeptide, vasoactive intestinal peptide, and growth hormone-releasing factor, respectively. Seven TGF-alpha-positive tumors were multihormonal, eight were monohormonal, and three were completely nonreactive for the regulatory substances studied. Except for its correlation with 5-hydroxytryptamine (serotonin) expression by the tumor cells, expression of TGF-alpha showed no significant association with other pathologic attributes, for example, the site of origin, size, depth of intramural penetration, metastases, and the secretory profiles of the tumors. These findings indicate that although TGF-alpha is expressed by a high proportion of GI carcinoids, the absence of its intact receptor molecule (EGFR) on the tumor cells renders it functionally ineffective as a growth factor. Thus, unlike in carcinomas of the GI tract, TGF-alpha appears to play no role in the growth and progression of GI carcinoids, which perhaps explains the indolent behavior and slow biological progression of GI carcinoids.
转化生长因子α(TGF-α)是一种属于表皮生长因子家族的强效生长因子,它通过与表皮生长因子受体(EGFR)结合,在正常细胞和肿瘤细胞的增殖与分化中发挥作用。癌组织中TGF-α和EGFR的共表达被认为赋予肿瘤细胞生长优势。为评估它们在诸如胃肠道(GI)类癌这种惰性肿瘤中的作用,我们调查了25例胃肠道类癌(9例前肠、13例中肠和3例后肠)中TGF-α和EGFR的免疫组化表达,并研究了它们的表达与这些肿瘤的分泌及临床病理特征之间的相关性。这些肿瘤中有18例(72%)表达TGF-α,17例肿瘤中有16例对EGFR的细胞外结构域呈免疫阳性,但均未表达其细胞内结构域。10例TGF-α阳性肿瘤对5-羟色胺呈阳性,7例对生长抑素呈阳性,3例对降钙素呈阳性,各有1例肿瘤分别对胃泌素、胰高血糖素、胰多肽、血管活性肠肽和生长激素释放因子呈阳性。7例TGF-α阳性肿瘤为多激素性,8例为单激素性,3例对所研究的调节物质完全无反应。除了与肿瘤细胞中5-羟色胺(血清素)表达相关外,TGF-α的表达与其他病理特征,如起源部位、大小、壁内浸润深度、转移以及肿瘤的分泌特征,均无显著关联。这些发现表明,尽管胃肠道类癌中有很大比例表达TGF-α,但肿瘤细胞上缺乏完整的受体分子(EGFR)使其作为生长因子在功能上无效。因此,与胃肠道癌不同,TGF-α似乎在胃肠道类癌的生长和进展中不起作用,这或许解释了胃肠道类癌的惰性行为和缓慢的生物学进展。